.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A11H_OtherPlainVitaminPreparations.A11HA06_PyridoxalPhosphate.PyridoxalPhosphate .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A11H_OtherPlainVitaminPreparations.A11HA06_PyridoxalPhosphate.PyridoxalPhosphate| name: | PyridoxalPhosphate |
| ATC code: | A11HA06 | route: |
| n-compartments | 1 |
Pyridoxal phosphate (PLP) is the active form of vitamin B6, functioning as a coenzyme in many enzymatic reactions including amino acid, glucose, and lipid metabolism. It is primarily used as a dietary supplement in cases of vitamin B6 deficiency and for certain rare metabolic disorders. Pyridoxal phosphate is not widely used as a drug itself but is essential in human metabolism. It is not approved as a therapeutic drug for most indications but is available as a supplement.
No published pharmacokinetic (PK) studies reporting model parameters (such as clearance, volume of distribution, etc.) for pyridoxal phosphate in humans were found in the scientific literature as of June 2024.
Kasama, R, et al., & Pitone, JM (1996). Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation 27(5) 680–686. DOI:10.1016/s0272-6386(96)90103-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8629628
Gill, SK, et al., & Koren, G (2011). Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin). Therapeutic drug monitoring 33(1) 115–119. DOI:10.1097/FTD.0b013e3181ff8bc5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21079545
Driskell, JA, et al., & Moak, SW (1989). Plasma pyridoxal 5'-phosphate concentrations in obese and nonobese black women residing near Petersburg, VA. The American journal of clinical nutrition 50(1) 37–40. DOI:10.1093/ajcn/50.1.37 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2750693